RARX News and Press, Ra Pharmaceuticals Inc. From 05/09/19

Ra Pharmaceuticals (NASDAQ: RARX ): Q1 GAAP EPS of -$0.45  beats by $0.04 . More news on: Ra Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Phase 2 gMG long-term extension data show durability of zilucoplan treatment effect, with sustained improvements in primary and secondary endpoints observed at 24 weeks Initiation of a single, pivotal, 12-week Phase 3 clinical trial in gMG on track for second half of 2019 Zilucopl...

Open-label, long-term extension data show durability of zilucoplan treatment effect, with sustained improvements observed in primary and secondary endpoints at 24 weeks Ra Pharmaceuticals, Inc.  (Nasdaq:RARX) today announced the presentation of data from the Company’s Pha...

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...

Noteworthy events during the latter part of the week of April 28 - May 4 for healthcare investors. More news on: UroGen Pharma Ltd., ESSA Pharma Inc., EyePoint Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

Zilucoplan XR achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting once weekly or less frequent dosing Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today presented pre-clinical data for an extended release (XR) formulation of zilucoplan ...

Ra Pharmaceuticals (NASDAQ: RARX ) is up  2%  premarket on light volume on the heels of its announcement that it has completed its End-of-Phase 2 interactions with the FDA and is putting the finishing touches on a pivotal Phase 3 study evaluating zilucoplan in patients with gene...

Alignment with FDA on a single, pivotal, 12-week, placebo-controlled, Phase 3 clinical trial to initiate in the second half of 2019 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the successful completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administratio...

From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that data from its Phase 2 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG) have been selected for an Emerging Science dual oral and poster presentation at the 2019 American Academy of Neurology (AAN)...